Pharma Mar (OTCMKTS:PHMMF) Short Interest Down 94.8% in July

Pharma Mar (OTCMKTS:PHMMF) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 13 shares, a decrease of 94.8% from the June 30th total of 252 shares. Based on an average trading volume of 93 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

A number of research firms have commented on PHMMF. BTIG Research started coverage on Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating on the stock. Zacks Research raised shares of Pharma Mar to a “hold” rating in a report on Monday, June 15th. Finally, Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Pharma Mar Price Performance

Shares of OTCMKTS:PHMMF remained flat at $86.09 during midday trading on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The firm’s 50-day moving average is $91.98 and its 200-day moving average is $93.84. Pharma Mar has a 1 year low of $77.41 and a 1 year high of $110.40.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.